Skip to main content
Unique mechanism of action
Navbar Image
Unique mechanism of action
This site is intended only for US healthcare professionals.

Unique mechanism of action

COSELA PROACTIVELY HELPS PROTECT AT THE SOURCE
BY PROTECTING THE PROGENITOR CELL, YOU’RE PROTECTING ALL OTHERS

In the clinical trials, only neutrophils, erythrocytes, and platelets were studied. Hematopoietic stem and progenitor cells, however, are the source of all blood lineages. Additional data is needed to evaluate efficacy beyond what is included in the presented studies.

  • Hematopoietic stem and progenitor cells are the source of multiple blood cell lineages that are critical for patients with ES-SCLC, but hematopoietic stem and progenitor cells are susceptible to chemotherapy damage, resulting in myelosuppression2
  • Unlike ES-SCLC cells, hematopoietic stem and progenitor cell proliferation is dependent on CDK 4 and 6 activity in the cell cycle1
  • COSELA can help protect the source of your patient’s neutrophils, red blood cells, and platelets starting with the first cycle of chemotherapy and administered throughout the course of treatment1
  • The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia

CDK=cyclin-dependent kinase; ES-SCLC=extensive-stage small cell lung cancer.